Five of Six Q4Bio Finalists Used IBM Quantum Hardware

Algorithmiq, working alongside the Cleveland Clinic and IBM, secured the 2 million prize in Wellcome Leap’s inaugural Q4Bio challenge, a competition designed to accelerate quantum computing applications in healthcare. The program, backed by an initial 40 million investment, required finalists to demonstrate scalable quantum algorithms on real quantum hardware; five of the six teams ultimately chose to run their large-scale demonstrations on IBM quantum computers. This preference underscores the role of quantum computers with over 100 qubits in addressing complex problems at the intersection of quantum science and practical healthcare solutions. Wellcome Leap funds high-risk, high-reward global health research, and this challenge reflects an expectation that viable quantum solutions are within a 3-5 year timeframe.

Q4Bio Challenge Drives Scalable Healthcare Algorithms

Five of six finalists in the recent Q4Bio Challenge used IBM quantum hardware, signaling a strong preference for the company’s systems among leading research teams tackling complex healthcare algorithms. The Wellcome Leap-funded challenge, backed by 40 million in funding and a 2 million prize, aimed to accelerate the development of quantum algorithms applicable to real-world healthcare problems within the next three to five years, and the results demonstrate a clear move toward practical application beyond theoretical exploration. Participants were tasked with demonstrating large-scale algorithms, requiring more than 50 qubits and circuit depths of 1,000 to 10,000 gates, alongside a viable path to future scalability. The winning team, Algorithmiq, in collaboration with the Cleveland Clinic and IBM, focused on simulating key processes in photodynamic therapy (PDT), a cancer treatment utilizing light-activated drugs.

Their success hinged on a novel “end-to-end hybrid quantum–classical framework” designed for large-scale molecular electronic structure simulations on IBM’s quantum hardware. By executing circuits on systems with up to 100 qubits, the team demonstrated a scalable approach toward achieving quantum advantage in drug discovery and development. Sabrina Maniscalco, CEO and co-founder of Algorithmiq, said that “This work provides one of the clearest indications to date that quantum computing can begin to impact real, chemically relevant problems, rather than simplified benchmarks,” emphasizing the practical implications of their findings.

Dr. Vijay Krishna, associate staff in biomedical engineering at Cleveland Clinic, added that “Q4Bio showed that when teams with complementary expertise work toward a common goal, they can make meaningful progress on problems that no single discipline can solve alone.” Beyond Algorithmiq’s win, the University of Oxford and Sanger Institute’s Quantum Pangenomics project achieved a first by encoding an entire genome onto a quantum computer. Utilizing an IBM Quantum Heron r2 processor, the team converted genome problems into quadratic unconstrained binary optimization (QUBO) formulations, relying on classical systems for problem formulation and analysis while leveraging quantum hardware for computationally intensive subproblems.

James McCafferty, Chief Information Officer at the Wellcome Sanger Institute, stated that “Encoding a whole genome onto a quantum computer is a world first and represents at least one order of magnitude improvement over any other efforts to represent DNA on quantum machines.” Sergii Strelchuk, associate professor of Computer Science at Oxford University, further clarified that “This is not a toy demonstration, it involves biologically significant sequences, represented on quantum hardware using data partitioning techniques and tailored depth-reduction we developed specifically for genomic data,” highlighting the project’s scalability and readiness. Infleqtion, working with the University of Chicago and MIT, also utilized IBM Quantum Heron r2 hardware for quantum-enhanced biomarker discovery from multimodal cancer data, demonstrating the potential of hybrid quantum-classical optimization algorithms. Fred Chong, Professor at University of Chicago and Chief Scientist for Quantum Software at Infleqtion, explained that Heron QPUs were the only available hardware capable of meeting the challenge’s criteria of exceeding 50 qubits and 1,000 quantum gates, allowing them to demonstrate a proof-of-concept for improved biomarker identification.

Algorithmiq’s Hybrid Approach Simulates Photodynamic Therapy

The pursuit of practical applications for quantum computing is rapidly shifting from theoretical possibility to demonstrable results, particularly within the healthcare sector. While fault-tolerant, universal quantum computers remain years away, researchers are increasingly focused on hybrid quantum-classical algorithms that can leverage the strengths of both computing paradigms to address pressing biological challenges. This approach is gaining traction, evidenced by a significant $40 million investment by Wellcome Leap into the Quantum for Bio (Q4Bio) challenge, designed to accelerate the development of these near-term solutions. The team’s success wasn’t simply about demonstrating a quantum algorithm; it involved a complete “end-to-end hybrid quantum–classical framework” capable of tackling a chemically complex problem. The team focused on simulating the molecular processes crucial to PDT, a task demanding significant computational resources.

This required not only advanced algorithms but also access to capable quantum hardware, a need that led five of the six Q4Bio Phase III finalists to utilize IBM quantum computers for their research. The ability to run circuits at this scale, and continuously validate the approach, was critical to identifying bottlenecks and ensuring robustness. The collaboration highlights the increasing importance of interdisciplinary teams in translating quantum research into tangible healthcare solutions.

Infleqtion & University of Chicago Validate Biomarker Discovery

This work, leveraging hybrid quantum-classical optimization algorithms, signifies a move beyond theoretical quantum computing and towards practical applications in healthcare, specifically in identifying indicators of disease before symptoms manifest. The team’s success hinged on utilizing IBM Quantum Heron r2 processors, which proved critical in meeting the stringent requirements set by Wellcome Leap’s Q4Bio challenge; these criteria demanded algorithms with over 50 quantum bits and a program length exceeding 1,000 quantum gates. The project’s immediate outcome is the identification of novel cancer biomarkers currently undergoing clinical evaluation, suggesting a tangible pathway from quantum research to patient care. The approach employed by Infleqtion and the University of Chicago involved a synergistic relationship between GPUs and quantum processing units (QPUs), an emerging trend in hybrid workflows designed to maximize computational power. This integration allowed researchers to tackle complex data analysis tasks that would be intractable for either classical or quantum systems alone. The results from Infleqtion and its collaborators represent a significant step toward realizing the potential of quantum computing to revolutionize disease detection and personalized medicine, offering a glimpse into a future where proactive healthcare is powered by the principles of quantum mechanics.